RNA Markers to Help Detect Endometriosis Early
Looks for gene signals that may help detect endometriosis in women of reproductive age.
Plain-language title generated from the registry record
Registry title: RNA Assays for Endometriosis Detection and Diagnosis
Key facts
- Where
- Branford, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 35 years old?
Source: NCT06907303, who can take part
Where in United States
- Wren LaboratoriesBranford, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wren Laboratories LLC
- Trial code
- NCT06907303
- Record updated
- 2 April 2025
- Original description
Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery. A key unmet need therefore is an accurate biomarker that can be used to detect the disease early. This study is a prospective trial to identify candidate mRNA-markers which can be used to aid in the diagnosis of this disease. It is a discovery/validation study that will identify and confirm a gene expression panel that is specific for endometriosis and provides a non-invasive tool for future use.Read full original descriptionShow less
Development and Evaluation of RNA-based Markers for Detecting and Diagnosing Endometriosis
Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery. A key unmet need therefore is an accurate biomarker that can be used to detect the disease early. This study is a prospective trial to identify candidate mRNA-markers which can be used to aid in the diagnosis of this disease. It is a discovery/validation study that will identify and confirm a gene expression panel that is specific for endometriosis and provides a non-invasive tool for future use.
Inclusion: For the endometriosis cohort; a history of infertility more than 1 year; age 20-35 years; normal liver and kidney function, without gynaecological and other systemic disease; -.
Exclusion: polycystic ovary syndrome, hyperprolactinemia; severe cardiovascular system, liver, kidney, and hematopoietic system disease; autoimmune disease; uterine fibroids, endometritis, non-vegetative ovarian cysts, ovarian malignancies, and internal genital tuberculosis; For the endometriosis cohort; -.